Inhibition of Chemokine Expression by Adenovirus Early Region Three (E3) Genes

Por Lesokhin, Alexander M., Delgado-Lopez, Fernando, Horwitz, Marshall S.
Publicado em 2002

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy

Por Lesokhin, Alexander M., Merghoub, Taha, Wolchok, Jedd D.
Publicado em 2013

Hiding the road signs that lead to tumor immunity

Por Schaer, David A., Lesokhin, Alexander M., Wolchok, Jedd D.
Publicado em 2011

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

Por Hirschhorn-Cymerman, Daniel, Rizzuto, Gabrielle A., Merghoub, Taha, Cohen, Adam D., Avogadri, Francesca, Lesokhin, Alexander M., Weinberg, Andrew D., Wolchok, Jedd D., Houghton, Alan N.
Publicado em 2009

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs

Por Nakahara, Takeshi, Uchi, Hiroshi, Lesokhin, Alexander M., Avogadri, Francesca, Rizzuto, Gabrielle A., Hirschhorn-Cymerman, Daniel, Panageas, Katherine S., Merghoub, Taha, Wolchok, Jedd D., Houghton, Alan N.
Publicado em 2010

A phase 2 single-center study of carfilzomib 56 mg/m(2) with or without low-dose dexamethasone in relapsed multiple myeloma

Por Lendvai, Nikoletta, Hilden, Patrick, Devlin, Sean, Landau, Heather, Hassoun, Hani, Lesokhin, Alexander M., Tsakos, Ioanna, Redling, Kaitlyn, Koehne, Guenther, Chung, David J., Schaffer, Wendy L., Giralt, Sergio A.
Publicado no Blood (2014)

T cell exhaustion in multiple myeloma relapse after autotransplant: Optimal timing of immunotherapy

Por Chung, David J., Pronschinske, Katherine B., Shyer, Justin A., Sharma, Sneh, Leung, Samantha, Curran, Shane A., Lesokhin, Alexander M., Devlin, Sean M., Giralt, Sergio A., Young, James W.
Publicado no Cancer Immunol Res (2015)

Self-antigen–specific CD8(+) T cell precursor frequency determines the quality of the antitumor immune response

Por Rizzuto, Gabrielle A., Merghoub, Taha, Hirschhorn-Cymerman, Daniel, Liu, Cailian, Lesokhin, Alexander M., Sahawneh, Diana, Zhong, Hong, Panageas, Katherine S., Perales, Miguel-Angel, Altan-Bonnet, Grégoire, Wolchok, Jedd D., Houghton, Alan N.
Publicado em 2009

Induction of tumoricidal function in CD4(+) T cells is associated with concomitant memory and terminally differentiated phenotype

Por Hirschhorn-Cymerman, Daniel, Budhu, Sadna, Kitano, Shigehisa, Liu, Cailian, Zhao, Feng, Zhong, Hong, Lesokhin, Alexander M., Avogadri-Connors, Francesca, Yuan, Jianda, Li, Yanyun, Houghton, Alan N., Merghoub, Taha, Wolchok, Jedd D.
Publicado em 2012

Monocytic CCR2+ Myeloid Derived Suppressor Cells Promote Immune Escape By Limiting Activated CD8 T Cell Infiltration Into The Tumor Microenvironment

Por Lesokhin, Alexander M., Hohl, Tobias M., Kitano, Shigehisa, Cortez, Czrina, Hirschhorn-Cymerman, Daniel, Avogadri, Francesca, Rizzuto, Gabrielle A., Lazarus, John J., Pamer, Eric G., Houghton, Alan N., Merghoub, Taha, Wolchok, Jedd D.
Publicado em 2011

Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency For Prediction of Clinical Outcomes

Por Kitano, Shigehisa, Postow, Michael A., Ziegler, Carly G.K., Kuk, Deborah, Panageas, Katherine S., Cortez, Czrina, Rasalan, Teresa, Adamow, Mathew, Yuan, Jianda, Wong, Philip, Altan-Bonnet, Gregoire, Wolchok, Jedd D., Lesokhin, Alexander M.
Publicado em 2014

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma

Por Lendvai, Nikoletta, Yee, Andrew J., Tsakos, Ioanna, Alexander, Aeri, Devlin, Sean M., Hassoun, Hani, Korde, Neha, Lesokhin, Alexander M., Landau, Heather, Mailankody, Sham, Koehne, Guenther, Chung, David J., Landgren, Ola, Raje, Noopur S., Giralt, Sergio
Publicado no Blood (2016)

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood

Por Murata, Kazunori, McCash, Samuel I, Carroll, Brittany, Lesokhin, Alexander M, Hassoun, Hani, Lendvai, Nikoletta, Korde, Neha S, Mailankody, Sham, Landau, Heather J, Koehne, Guenther, Chung, David J, Giralt, Sergio A, Ramanathan, Lakshmi V, Landgren, Ola
Publicado no Clin Biochem (2016)

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

Por Postow, Michael A, Cardona, Diana M, Taube, Janis M, Anders, Robert A, Taylor, Clive R, Wolchok, Jedd D, Callahan, Margaret K, Curran, Michael A, Lesokhin, Alexander M, Grosso, Joseph F, Horak, Christine E, Cogswell, John, Simon, Jason S, Gupta, Ashok K, Sznol, Mario
Publicado em 2014

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

Por Postow, Michael A., Callahan, Margaret K., Barker, Christopher A., Yamada, Yoshiya, Yuan, Jianda, Kitano, Shigehisa, Mu, Zhenyu, Rasalan, Teresa, Adamow, Matthew, Ritter, Erika, Sedrak, Christine, Jungbluth, Achim A., Chua, Ramon, Yang, Arvin S., Roman, Ruth-Ann, Rosner, Samuel, Benson, Brenna, Allison, James P., Lesokhin, Alexander M., Gnjatic, Sacha, Wolchok, Jedd D.
Publicado em 2012

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Por Ansell, Stephen M., Lesokhin, Alexander M., Borrello, Ivan, Halwani, Ahmad, Scott, Emma C., Gutierrez, Martin, Schuster, Stephen J., Millenson, Michael M., Cattry, Deepika, Freeman, Gordon J., Rodig, Scott J., Chapuy, Bjoern, Ligon, Azra H., Zhu, Lili, Grosso, Joseph F., Kim, Su Young, Timmerman, John M., Shipp, Margaret A., Armand, Philippe
Publicado no N Engl J Med (2014)

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

Por Naidoo, Jarushka, Schindler, Katja, Querfeld, Christiane, Busam, Klaus, Cunningham, Jane, Page, David B., Postow, Michael A., Weinstein, Alyona, Lucas, Anna Skripnik, Ciccolini, Kathryn T., Quigley, Elizabeth A., Lesokhin, Alexander M., Paik, Paul K., Chaft, Jamie E., Segal, Neil H., D‘Angelo, Sandra P., Dickson, Mark, Wolchok, Jedd D., Lacouture, Mario E.
Publicado no Cancer Immunol Res (2016)

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

Por Callahan, Margaret K, Horak, Christine E, Curran, Michael A, Hollman, Travis, Schaer, David A, Yuan, Jianda, Lesokhin, Alexander M, Kitano, Shigehisa, Hong, Quan, Ariyan, Charlotte E, Busam, Klaus J, Feely, William, Jure-Kunkel, Maria, Grosso, Joseph, Simon, Jason S, Korman, Alan J, Wigginton, Jon M, Gupta, Ashok K, Zhang, Xiaoling, Phillips, Therese, Simmons, Pauline, Sznol, Mario, Wolchok, Jedd D
Publicado em 2013

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Por Lesokhin, Alexander M., Ansell, Stephen M., Armand, Philippe, Scott, Emma C., Halwani, Ahmad, Gutierrez, Martin, Millenson, Michael M., Cohen, Adam D., Schuster, Stephen J., Lebovic, Daniel, Dhodapkar, Madhav, Avigan, David, Chapuy, Bjoern, Ligon, Azra H., Freeman, Gordon J., Rodig, Scott J., Cattry, Deepika, Zhu, Lili, Grosso, Joseph F., Bradley Garelik, M. Brigid, Shipp, Margaret A., Borrello, Ivan, Timmerman, John
Publicado no J Clin Oncol (2016)